CBI’s Pharmaceutical Congress on Paragraph IV Disputes

The Center for Business Intelligence is hosting the above titled conference in Philadelphia, PA on October 15 - 16, 2008.

Paragraph IV litigation is reaching an all-time high with almost $85 billion in product sales that potentially could be affected by pending litigation and more than twenty-five drugs going off patent before 2012.  Today’s pharmaceutical companies, both brand and generic, have much at stake in this costly, complex and constantly changing area of patent litigation.  CBI’s Pharmaceutical Congress on Paragraph IV Disputes brings both sides of the issue together for two days of presentations and panel discussions to discuss litigation strategies, statutory guidelines, current cases and their landmark decisions.

Topics to be discussed include:

• FTC address on pharmaceutical antitrust
• In depth analysis of recent court cases and their implications on brand and generic companies
• Effects of KSR on brand and generic litigation strategies
• Panel discussion on acceptable settlement strategies for paragraph IV disputes
• Litigating paragraph IV disputes with multiple ANDA filers
• Interpreting forfeiture provisions for better business decisions
• Pre-suit preparedness strategies for paragraph IV disputes
• Citizen petitions and their impact on generic entry
• Declaratory judgments
• At risk launches

More information and registration details are available here.